Compare BCTX & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCTX | CCEL |
|---|---|---|
| Founded | 2014 | 1989 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Managed Health Care |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8M | 32.7M |
| IPO Year | N/A | 1997 |
| Metric | BCTX | CCEL |
|---|---|---|
| Price | $4.04 | $3.43 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $40.00 | N/A |
| AVG Volume (30 Days) | ★ 429.3K | 15.1K |
| Earning Date | 03-11-2026 | 03-02-2026 |
| Dividend Yield | N/A | ★ 4.38% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $31,747,500.00 |
| Revenue This Year | N/A | $0.30 |
| Revenue Next Year | $380.95 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.01 | $3.10 |
| 52 Week High | $98.20 | $8.20 |
| Indicator | BCTX | CCEL |
|---|---|---|
| Relative Strength Index (RSI) | 37.31 | 48.04 |
| Support Level | $4.01 | $3.27 |
| Resistance Level | $4.42 | $3.49 |
| Average True Range (ATR) | 0.28 | 0.19 |
| MACD | 0.13 | 0.02 |
| Stochastic Oscillator | 5.23 | 68.23 |
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.